Buy Max Healthcare Institute; target of Rs 427: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Max Healthcare Institute has recommended buy rating on the stock with a target price of Rs 427 in its research report dated August 13, 2022.

Broker Research

August 16, 2022 / 17:00 IST

Rama Steel Tubes: Nomura Singapore buys 1 lakh shares in Rama Steel Tubes. Nomura Singapore bought 1 lakh equity shares in the company via open market transactions on June 15. These shares were acquired at an average price of Rs 371 per share.

26 Aug, 2025 12:21

Volume

Todays L/H

Prabhudas Lilladher's research report on Max Healthcare Institute

Max Healthcare (MAXHEALT) reported EBIDTA of Rs3.7bn (up 23% QoQ) vs our estimate of Rs3.6bn. Overall occupancy stood at 74% vs 68% in Q4, while ARPOB grew healthy at Rs.66K, 4% QoQ due to annual price revisions and improvement in payor & surgical mix. Net debt decreased by Rs 2.2bn QoQ to Rs 2.1bn. MAXHEALT operational efficiency has been commendable, especially in competitive markets like NCR. Company showed phenomenal growth in past two years and we expect this momentum to continue with 1) strong expansion plans, 2) improving payor mix and 3) scale up in labs. Our FY23E and FY24E EBIDTA stands increased by 5% and 2% respectively.

Outlook

We expect 16% EBITDA CAGR over FY22-24E. FY22 had one-time contribution from vaccine and COVID revs. We maintain our ‘Buy’ rating at TP of Rs427/share.

For all recommendations report, click here